Indian J Tuberc
January 2019
Background/objective: Vitamin D deficiency may contribute to the therapeutic failure of antituberculosis therapy (ATT). The aim of this study is to explore the role of adding cholecalciferol to the standard ATT in improving the therapeutic outcome among the naïve patients with pulmonary tuberculosis (TB).
Methods: A randomized, controlled, clinical study, which included 496 naïve patients with pulmonary TB, was carried out.
Objective: To determine the frequency of therapeutic failure among patients with acute and subacute brucellosis and to explore the predictors of failure.
Methods: The study included 213 consecutive, naïve patients with acute and subacute brucellosis. All participants underwent clinical evaluation, chest radiography, stool microscopic examination and interferon-gamma release assay.
Int J Mycobacteriol
February 2018
Background: Patients in countries endemic for chronic viral hepatitis are more vulnerable to antituberculosis therapy-induced liver disorders (ATT-LDs). The aim of this study was to explore the role of cholecalciferol in prophylaxis against ATT-LD among patients with pulmonary tuberculosis (TB) receiving ATT.
Material And Methods: We conducted a hospital-based, prospective, randomized, comparative study which included 300 consecutive, naïve patients with pulmonary TB eligible for ATT.
Int J Mycobacteriol
December 2015
Objective/background: The aim of this study is to determine the rate of hookworm infection among patients with pulmonary tuberculosis (TB) and to find out if there is a relation between hookworm infection and the therapeutic failure of pulmonary TB.
Methods: We carried out a prospective, hospital-based study. The study included 231 naïve patients with pulmonary TB, consecutively.